Clinical Trials

With a key investor conference ahead, MacroGenics balances promising cancer drug data against a history of clinical setbacks and a major strategic pivot.

Dr. Timothy Donahue's new leadership at Weill Cornell while on Trethera's board highlights a key trend: integrating top clinical minds to accelerate drug development.

With Phase 3 data imminent and a new Nasdaq ticker, Helus Pharma is using a key investor conference to frame its novel therapies as the next frontier.

As Cardiol Therapeutics prepares for a key investor conference, it's not just a presentation; it's a test of its strategy to build a durable franchise in heart disease.

With a key conference appearance, OPKO Health aims to translate its deep R&D pipeline into market confidence. Will investors buy into its long-term vision?

While we focus on breakthrough drugs, the real story is often in the logistics. GCCL’s expansion into Asia-Pacific highlights the critical, and lucrative, world of clinical trial support.

With over a billion in the bank, Spyre Therapeutics is hitting the investor circuit. But cash is only half the story. Can upcoming data validate its ambitious strategy?

A deep dive into PRF Technologies' audacious dual-engine strategy, as it simultaneously pushes for FDA trials and commercializes AI for the green energy grid.

As advanced therapies reshape medicine, the race to control their complex supply chains heats up. Resonant's latest acquisition places it at the heart of Europe's booming market.

Tangram Therapeutics signals a major strategic push, advancing its novel MASH drug into patient trials while hiring a veteran CDO to steer its pipeline.

As Stoke prepares for a key investor conference, its lead drug zorevunersen nears a pivotal Phase 3 readout, promising a new era for patients and the RNA platform.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

As it launches a pivotal trial for its MYC inhibitor, Persevere Therapeutics adds a seasoned CEO to its board, signaling a sharp focus on funding and strategy.

Monash Health's landmark deal with Germany's Data4Life isn't just about tech; it's a strategic play to redefine global clinical research using open-source power.

With its new COVID vaccine approved, Novavax is leveraging global partners like Sanofi to earn royalties, proving an asset-light model can rival industry giants.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

Allegheny Health Network and START's new partnership isn't just a local win; it's a blueprint for a more accessible, patient-centric future in oncology.

A small biophysics firm unveils promising data for its at-home headset using magnetic fields to treat Long COVID, heralding a potential shift from pharma to biophysics.

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.